@article{ATM23699,
author = {Wenda Ye and Nicole C. Schmitt},
title = {Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients?},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 1},
year = {2019},
keywords = {},
abstract = {Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide, with more than half a million new cases every year (1). Over half of these originate from the Asia Pacific region, where HNSCC accounts for a much greater proportion of newly diagnosed cancers (2). While the annual incidence of HNSCC in North America and Europe ranges from 5–10% of new cancer cases, this figure may be as high as 37.5% in some areas of Asia (3).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/23699}
}